BRPI0816712A2 - terapia de intervalo para o tratamento de tinnitus - Google Patents

terapia de intervalo para o tratamento de tinnitus

Info

Publication number
BRPI0816712A2
BRPI0816712A2 BRPI0816712A BRPI0816712A BRPI0816712A2 BR PI0816712 A2 BRPI0816712 A2 BR PI0816712A2 BR PI0816712 A BRPI0816712 A BR PI0816712A BR PI0816712 A BRPI0816712 A BR PI0816712A BR PI0816712 A2 BRPI0816712 A2 BR PI0816712A2
Authority
BR
Brazil
Prior art keywords
tinnitus
treatment
interval therapy
therapy
interval
Prior art date
Application number
BRPI0816712A
Other languages
English (en)
Portuguese (pt)
Inventor
Barbara Ellers-Lenz
Hagen Krueger
Hermann Russ
Michael Althaus
Tanja Rosenberg
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0816712A2 publication Critical patent/BRPI0816712A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0816712A 2007-09-12 2008-09-10 terapia de intervalo para o tratamento de tinnitus BRPI0816712A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US99339607P 2007-09-12 2007-09-12
EP07253630 2007-09-12
US6702608P 2008-02-25 2008-02-25
US6708308P 2008-02-25 2008-02-25
US6693108P 2008-02-25 2008-02-25
EP08004778 2008-03-14
EP08004776 2008-03-14
EP08004777 2008-03-14
PCT/EP2008/007418 WO2009033649A1 (fr) 2007-09-12 2008-09-10 Thérapie à intervalle pour le traitement d'un acouphène

Publications (1)

Publication Number Publication Date
BRPI0816712A2 true BRPI0816712A2 (pt) 2016-11-08

Family

ID=40451596

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0816712A BRPI0816712A2 (pt) 2007-09-12 2008-09-10 terapia de intervalo para o tratamento de tinnitus
BRPI0816690A BRPI0816690A2 (pt) 2007-09-12 2008-09-10 derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0816690A BRPI0816690A2 (pt) 2007-09-12 2008-09-10 derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição

Country Status (21)

Country Link
US (6) US9468610B2 (fr)
EP (6) EP2200599B1 (fr)
JP (6) JP5563460B2 (fr)
KR (4) KR20100052558A (fr)
CN (4) CN101801365A (fr)
AR (3) AR071728A1 (fr)
AT (1) ATE532507T1 (fr)
AU (4) AU2008298016B2 (fr)
BR (2) BRPI0816712A2 (fr)
CA (4) CA2699209A1 (fr)
DK (1) DK2200600T3 (fr)
ES (5) ES2377253T3 (fr)
HR (1) HRP20120046T1 (fr)
MX (4) MX2010002734A (fr)
PL (1) PL2200600T3 (fr)
PT (1) PT2200600E (fr)
RU (1) RU2011137131A (fr)
SI (1) SI2200600T1 (fr)
TW (3) TW200922544A (fr)
WO (4) WO2009033652A1 (fr)
ZA (4) ZA201001262B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120046T1 (hr) * 2007-09-12 2012-02-29 Merz Pharma Gmbh & Co. Kgaa Nerameksan za uporabu kod liječenja subakutnog tinitusa
US20110294890A1 (en) 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
JP2013529604A (ja) * 2010-06-24 2013-07-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ネラメキサン複数単位剤形
WO2012098000A1 (fr) 2011-01-20 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Néramexane pour le traitement ou la prévention de l'acouphène relatif au stress ou à une perte d'audition aiguë
WO2014138502A1 (fr) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Dosage thérapeutique d'une neuréguline ou d'un fragment associé pour le traitement ou la prophylaxie de l'insuffisance cardiaque
CA2946146A1 (fr) * 2014-04-28 2015-11-05 Kyorin Pharmaceutical Co., Ltd. Medicament pour le traitement de patients ayant des d'acouphenes
MX2016014011A (es) * 2014-04-28 2017-01-11 Kyorin Seiyaku Kk Farmaco para el tratamiento de pacientes con tinnitus.
EP3209291B1 (fr) 2014-10-23 2023-12-06 Arena Pharmaceuticals, Inc. Procédé de traitement de troubles liés au récepteur pgi2
EP3297628B1 (fr) * 2015-05-18 2021-06-09 Sensorion Azasétron pour son utilisation dans le traitement de la perte auditive
KR101893604B1 (ko) 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
CN105924362B (zh) * 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
US12433865B2 (en) 2018-05-16 2025-10-07 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
KR102268893B1 (ko) 2020-01-16 2021-06-24 경북대학교 산학협력단 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물
CN111477199B (zh) * 2020-04-02 2021-11-30 北京瑞迪欧文化传播有限责任公司 一种嵌入式音乐控制系统
EP4297708A4 (fr) * 2021-09-09 2024-08-28 Samsung Electronics Co., Ltd. Gestion de distribution de contenu audio

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
DK0724432T3 (da) 1993-10-22 2003-01-27 Genentech Inc Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
WO1998010757A2 (fr) 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
ATE240936T1 (de) * 1997-06-30 2003-06-15 Merz & Co Gmbh & Co 1-amino-alkylcyclohexane als nmda-rezeptor- antagonisten
EE200200612A (et) * 2000-04-26 2004-06-15 Warner-Lambert Company Tsükloheksüülamiini derivaadid kui alatüübi selektiivsed NMDA-retseptori antagonistid
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
JP2004021734A (ja) 2002-06-18 2004-01-22 Nokia Corp キーパッドおよびキーパッドシステム
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
CA2497867A1 (fr) * 2002-09-06 2004-03-18 Durect Corporation Administration dans l'oreille interne de modulateurs de la neurotransmission glutamatergique
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
AU2004251636B2 (en) * 2003-05-27 2006-11-09 Merz Pharma Gmbh & Co. Kgaa Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
EP2397122B1 (fr) * 2004-06-17 2014-05-14 Merz Pharma GmbH & Co. KGaA Formulations de formes pharmaceutiques de néramexane
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2594963A1 (fr) * 2005-01-24 2006-07-27 Neurosystec Corporation Appareil et methode permettant de distribuer des agents therapeutiques et/ou autres a l'oreille interne et a d'autres tissus
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
TWI265036B (en) * 2005-04-29 2006-11-01 Guo-Ming Huang Safety injector and method of operating the same
ES2357093T3 (es) * 2005-05-18 2011-04-18 Gt Urological, Llc Elución de fármaco para dispositivos para la incontinencia implantables.
CN1896729A (zh) 2005-07-15 2007-01-17 复旦大学附属中山医院 纳米药物自组装双稳态量子线阵列及其制备方法
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
HRP20120046T1 (hr) * 2007-09-12 2012-02-29 Merz Pharma Gmbh & Co. Kgaa Nerameksan za uporabu kod liječenja subakutnog tinitusa
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
RU2011113733A (ru) * 2008-09-10 2012-10-20 Мерц Фарма Гмбх Унд Ко. Кгаа (De) Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2012098000A1 (fr) * 2011-01-20 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Néramexane pour le traitement ou la prévention de l'acouphène relatif au stress ou à une perte d'audition aiguë

Also Published As

Publication number Publication date
WO2009033649A1 (fr) 2009-03-19
JP2014221767A (ja) 2014-11-27
ZA201001263B (en) 2011-07-27
WO2009033651A1 (fr) 2009-03-19
BRPI0816690A2 (pt) 2016-11-01
CN101801366A (zh) 2010-08-11
EP2386299A2 (fr) 2011-11-16
ES2596262T3 (es) 2017-01-05
JP2010539116A (ja) 2010-12-16
CA2699210A1 (fr) 2009-03-19
ZA201001261B (en) 2011-08-31
ES2562709T3 (es) 2016-03-07
EP2548552B1 (fr) 2015-11-18
EP2200600B1 (fr) 2011-11-09
KR20100052556A (ko) 2010-05-19
US8877814B2 (en) 2014-11-04
US20100298440A1 (en) 2010-11-25
AU2008298016A1 (en) 2009-03-19
JP5613053B2 (ja) 2014-10-22
CA2699213A1 (fr) 2009-03-19
DK2200600T3 (da) 2012-01-23
MX2010002733A (es) 2010-04-09
EP2200598A1 (fr) 2010-06-30
EP2548552A3 (fr) 2013-10-16
US20110077304A1 (en) 2011-03-31
JP2010539118A (ja) 2010-12-16
CN101835469A (zh) 2010-09-15
AU2008298017B2 (en) 2012-03-01
AU2008298018A1 (en) 2009-03-19
US20170027885A1 (en) 2017-02-02
KR20100052557A (ko) 2010-05-19
US9468610B2 (en) 2016-10-18
ZA201001262B (en) 2011-07-27
JP5784189B2 (ja) 2015-09-24
JP5563460B2 (ja) 2014-07-30
EP2386299A3 (fr) 2012-05-02
WO2009033652A1 (fr) 2009-03-19
AU2008298018C1 (en) 2012-08-16
EP2200599B1 (fr) 2016-08-31
EP2203163A1 (fr) 2010-07-07
KR20100052559A (ko) 2010-05-19
AU2008298016B2 (en) 2012-02-02
AR070026A1 (es) 2010-03-10
US20100298441A1 (en) 2010-11-25
CA2699207A1 (fr) 2009-03-19
JP2014221766A (ja) 2014-11-27
JP5612473B2 (ja) 2014-10-22
US20150018425A1 (en) 2015-01-15
EP2203163B1 (fr) 2014-08-27
TW200922544A (en) 2009-06-01
MX2010002736A (es) 2010-04-01
AR070025A1 (es) 2010-03-10
EP2548552A2 (fr) 2013-01-23
EP2200599A1 (fr) 2010-06-30
ES2377253T3 (es) 2012-03-23
JP2010539115A (ja) 2010-12-16
AR071728A1 (es) 2010-07-14
CN101801365A (zh) 2010-08-11
ZA201001264B (en) 2011-07-27
US9498450B2 (en) 2016-11-22
ES2604945T3 (es) 2017-03-10
AU2008298015B2 (en) 2012-03-22
TW200927087A (en) 2009-07-01
CN101795679A (zh) 2010-08-04
EP2200600A1 (fr) 2010-06-30
KR20100052558A (ko) 2010-05-19
US20110086916A1 (en) 2011-04-14
ATE532507T1 (de) 2011-11-15
AU2008298018B2 (en) 2012-01-19
AU2008298017A1 (en) 2009-03-19
AU2008298015A1 (en) 2009-03-19
SI2200600T1 (sl) 2012-03-30
RU2011137131A (ru) 2013-03-20
EP2386299B1 (fr) 2016-07-13
WO2009033650A1 (fr) 2009-03-19
JP5784188B2 (ja) 2015-09-24
HRP20120046T1 (hr) 2012-02-29
PL2200600T3 (pl) 2012-04-30
JP2010539117A (ja) 2010-12-16
ES2510565T3 (es) 2014-10-21
CA2699209A1 (fr) 2009-03-19
JP5563461B2 (ja) 2014-07-30
PT2200600E (pt) 2012-02-17
MX2010002735A (es) 2010-04-01
TW200918042A (en) 2009-05-01
MX2010002734A (es) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0922771A2 (pt) agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BR112012008959A2 (pt) tratamento de terapia de combinação para infecções virais

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]